$BIVI News

BioVie Announces Full Enrollment Of ADDRESS-LC Phase 2 Trial Evaluating Drug Candidate Bezisterim For Treatment Of Neurological Symptoms Of Long COVID

BioVie Announces Completion Of Last Patient Evaluation Visit In The SUNRISE-PD Phase 2 Trial Evaluating Its Drug Candidate Bezisterim In Early Stage Parkinson's Disease

BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript

BioVie advances long COVID trial, top-line data expected by summer

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie To Host Virtual Key Opinion Leader Event On May 7 To Discuss Phase 2 Trial Of Bezisterim To Treat Parkinson's Disease

RedChip's Biotech Investor Conference Replays Now Available

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

BioVie abstract on Parkinson’s drug accepted for neurology conference

BioVie CEO explains Bezisterim Parkinson’s trial results - ICYMI

BioVie targets neuroinflammation and insulin resistance in Parkinson’s treatment approach

BioVie to present Parkinson’s study data at AD/PD 2026 conference

BioVie Announces Abstract Accepted for Presentation at AD/PD 2026

BioVie Inc. (BIVI) Discusses Clinical Progress of Bezisterim Targeting Inflammation in Parkinson's, Alzheimer's, and Long COVID Transcript

60 Degrees Pharmaceuticals and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4

New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin America

BioVie highlights bezisterim research at ACP meeting

BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting

BioVie Announces Its Two Abstracts From Studies On Bezisterim To Treat Alzheimer's Disease, Long COVID Accepted At 2026 American College of Psychiatrists Annual Meeting